Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir and Clarithromycin Interaction Study
NCT02251769Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2003
- Primary completion
- Sep 2003
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under plasma concentration time curve from 0-12 hours, Maximum plasma concentration up to 12 hours and 1 more. Started Aug 2003; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251769.